by ComplianceQuest

My Dashboard Inspection Tracker FDA Guidance Templates Assessments

Sign in Get started

Tracker Overview Enforcement Themes Form 483s Warning Letters Inspections Recalls Investigators Companies Facilities

ANALYTICS

Tracker Overview Enforcement Themes

FDA ACTIONS

Form 483s Warning Letters Inspections Recalls

AUDIT READINESS

COMPANIES

Companies Facilities

Loading…

Dashboard Warning LettersWarning Letter Details

New Life Pharma LLC Warning Letter Details

Warning Letter

New Life Pharma LLC

Recipient Title Director, QA, 265 Livingston Street Northvale , NJ 07647-1901 United States

Issue DateApril 14, 2026

FEI Number3012113519

Violations6

CountryUnited States

Issuing Office

Center for Drug Evaluation and Research (CDER)

Product Type

Drugs

Status

Open

Subject

CGMP/Adulterated and Unapproved New Drug/Misbranded

New Life Pharma LLC FDA Warning Letter, April 14, 2026